Novo and Sanofi make case for hypo-reducing insulins at EASD

Novo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals trying to make the case for their competing insulins and their ability to reduce risk of dangerous “hypos” in patients with type 2 diabetes.